Arax Advisory Partners’s Alto Neuroscience ANRO Stock Holding History

Arax Advisory Partners’s Portfolio ANRO Stock Details ANRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$132	Hold	5	–	–	﹤0.01%	5125
2026 Q1	$112	Hold	5	–	–	﹤0.01%	3602
2025 Q4	$89	Sell	5 -37	-88%	-$466	﹤0.01%	3848
2025 Q3	$169	Buy	+42	New	+$139	﹤0.01%	3461

Other funds holding ANRO

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SSC

Spruce Street Capital New York $510M AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Arax Advisory Partners's ANRO Position: Q2 2026 in Review

Arax Advisory Partners held its Alto Neuroscience (ANRO) position steady in Q2 2026 at 5 shares worth $132. The position accounts for ﹤0.01% of the portfolio, ranked #5125.

Arax Advisory Partners first reported a position in ANRO in Q3 2025 and has held it in 4 quarters since. The position peaked at $169 in Q3 2025. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

Arax Advisory Partners held 5 shares of Alto Neuroscience worth $132 as of Q2 2026.
Arax Advisory Partners left its Alto Neuroscience share count unchanged in Q2 2026.
Alto Neuroscience made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #5125 holding.
Arax Advisory Partners first reported a position in Alto Neuroscience in Q3 2025 and has held it in 4 quarters since.
Arax Advisory Partners's Alto Neuroscience position peaked at $169 in Q3 2025.
114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.